Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 11/20 | 0.52 |
| ▸ | AKT1S1 | Q96B36 | 2/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.51 |
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | MC1R | Q01726 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2836180 | 0.85 | CCR3 (0.50) | MC4RRPS6KB1CCR3 | |
| SCHEMBL3471054 | 0.84 | RPS6KB1 (0.51) | AKT1S1RPS6KB1 | |
| SCHEMBL26921276 | 0.83 | CHRM2 (0.55) | MC4RAKT1S1RPS6KB1 | |
| SCHEMBL2843665 | 0.83 | MC4R (0.62) | MC4RRPS6KB1CCR3 | |
| SCHEMBL25375773 | 0.83 | MC4R (0.62) | MC4RRPS6KB1CCR3 | |
| SCHEMBL3470901 | 0.80 | ACHE (0.53) | AKT1S1RPS6KB1 | |
| SCHEMBL15719671 | 0.80 | SLC6A4 (0.58) | MC4RAKT1S1RPS6KB1 | |
| Hydrochloric Acid SCHEMBL17107316 | 0.79 | SLC6A4 (0.57) | MC4RAKT1S1RPS6KB1 | |
| SCHEMBL16460909 | 0.79 | P2RX7 (0.48) | AKT1S1RPS6KB1 | |
| SCHEMBL7395502 | 0.77 | CYP2D6 (0.66) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2044031-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | Bayer HealthCare AG (DE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006479-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105663-A1 | 2-(HETEROARYL) ALKYL INDAZOLE 6-PHENYL AND THIENYL METHYL AMIDE AS THROMBIN INHIBITORS | F2, TFPI, PLAT | MC4R 2957/4885AKT1S1 3067/4885RPS6KB1 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.